NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Nana Gletsu Miller
Conditions: Obesity, Adolescent, Dietary Sugars, Taste Perception, Insulin Resistance, Feeding Behavior
Interventions: Unsweetened Sparkling Water Replacement, Progressively Reduced Sugar Beverage Replacement, Plain Water Replacement
Countries: United States
The goal of this clinical trial is to test whether replacing sugary sodas with unsweetened, flavored sparkling waters can reduce added sugar intake and improve health in Black/African American and Latine adolescents with obesity who prefer sweet-tasting beverages. The main questions it aims to answer are: * Does replacing sugary sodas with water change liking for sugary drinks, and water? * Do shifts in liking for sweetness lead to improved diet quality and cardiometabolic health? Researchers will compare replacing sugary sodas with one of three alternative beverages: unsweetened sparkling water, plain water, and beverages with gradually reduced sugar to determine which strategy is most effective. Participants will: * Replace sugary sodas with study drinks for 4 weeks * Complete taste tests to measure their liking for and sensory experience of sweetness over 8-weeks * Provide dietary recalls, body measurements, and blood samples over 8-weeks
Sex: ALL
Age: 12 Years to 18 Years
Healthy volunteers: Yes
Study type: INTERVENTIONAL
Inclusion Criteria: * Adolescents ages 12 to 18 who display a "sweet-liker" pattern, characterized by a preference for higher concentrations of sugar in beverages, specifically identifying 0.3M (10.3% sucrose) or above as their most liked sample. * Adolescents consumes sugar-sweetened soda greater than or equal to 2 times per week. Adolescents must also indicate a willingness to drink study beverages; not currently dieting/changing diet. Exclusion Criteria: * Adolescent participant is pregnant, since pregnancy affects taste perception * Participant is allergic or intolerant to the items we are testing. * Adolescent with type 1 or type 2 diabetes (self-declared or detected at screening visit through fasting glucose) * Use of GLP-1 receptor agonists intended for weight loss.
- Bloomington, Indiana, United States
- Indianapolis, Indiana, United States
- West Lafayette, Indiana, United States